Drug intelligence / Profile preview

Aflubin

Development stage
Unknown
Lead developer
Bittner
Administration
Oral, Sublingual
01

Overview

**Aflubin** is a complex homeopathic preparation used primarily for the prevention and treatment of influenza, common colds (ARVI), and as adjunctive therapy for inflammatory and rheumatic diseases with joint pain. It contains highly diluted active ingredients including Aconitum napellus D6, Bryonia cretica D6, Eupatorium perfoliatum D2 (or similar), Ferrum phosphoricum D12, Gentiana lutea D1, and Acidum lacticum D12, formulated in drops or sublingual tablets. The preparation exhibits anti-inflammatory, immunomodulatory, antipyretic, detoxifying, and claimed antiviral effects by stimulating interferon synthesis, enhancing cellular and local immunity, reducing fever, chills, runny nose, cough, headache, muscle/joint pain, and supporting recovery while preventing complications. Available in oral drops (e.g., 20ml, 50ml containing ~43% ethanol) and tablets, it is produced in Ukraine and marketed in Europe for symptomatic relief of flu-like symptoms.[1][2][5][8]

Brand names
Aflubin

Beyond the preview

Go deeper on Aflubin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aflubin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call